Phaseline

Targets › SURVIVIN

SURVIVIN: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on SURVIVIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Catherine BollardTumor associated antigen lymphocytes (TAA-T)
Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN
WT1, PRAME, SURVIVINPhase 1Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain TumorNov 2026

Conditions

Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1)

Modalities

protein or peptide (1)

Companies

Catherine Bollard (1)

Related targets

WT1 (1) PRAME (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.